International Technologist in Cytogenetics ASCP Practice Test

Acute Megakaryocytic Leukemia (AMKL) is classified under the AML M7 subtype. This designation is based on the predominant blast cell type in AMKL, which is characterized by megakaryoblasts. These blasts are larger than typical myeloid cells and can often be identified by specific morphological features and immunophenotypes, such as the expression of platelet-associated antigens.

In the context of acute myeloid leukemia (AML) subtypes, M7 is specifically recognized for its connection to megakaryocytic lineage. AMKL may also be associated with genetic abnormalities, such as mutations in the GATA1 gene, or with conditions like Down syndrome. Recognizing AMKL as M7 is essential for diagnosis and treatment planning, contributing to better patient management and understanding of the disease.

Other subtypes of AML are categorized based on different characteristics: AML M5 is associated with monocytic differentiation, AML M6 with erythroid differentiation, and AML M4 with myelomonocytic differentiation. Each of these subtypes has distinct clinical features and, consequently, different approaches to treatment.